Terms: = Prostate cancer AND CCNE1, CCNE, 898, ENSG00000105173, P24864 AND Treatment
35 results:
1. Cardiometabolic comorbidities in Hispanic/Latino cancer survivors: prevalence and impact on health-related quality of life and supportive care needs.
Maras AF; Penedo FJ; Ramirez AG; Worch SM; Ortiz MS; Yanez B; Munoz E; Lad T; Hollowell C; Medina HN; Moreno PI
Support Care Cancer; 2023 Nov; 31(12):711. PubMed ID: 37982906
[TBL] [Abstract] [Full Text] [Related]
2. Prediction of Resistance to
Sartor O; Ledet E; Huang M; Schwartz J; Lieberman A; Lewis B; Layton J; Barata P; Jang A; Hawkins M; Pocha O; Lanka S; Harris K
J Nucl Med; 2023 Nov; 64(11):1721-1725. PubMed ID: 37770113
[No Abstract] [Full Text] [Related]
3. Clinical Outcomes of First Subsequent Therapies After Abiraterone Acetate Plus Prednisone for High-Risk Metastatic Castration-Sensitive prostate cancer in the LATITUDE Study.
Koroki Y; Taguri M
Target Oncol; 2023 Jan; 18(1):119-128. PubMed ID: 36443540
[TBL] [Abstract] [Full Text] [Related]
4. Intermediate-term oncological outcomes after a negative endorectal coil multiparametric MRI of the prostate in patients without biopsy proven prostate cancer.
Kamal O; Comerford J; Foster BR; Young DJ; Amling C; Coakley FV
Clin Imaging; 2022 Dec; 92():112-116. PubMed ID: 36306588
[TBL] [Abstract] [Full Text] [Related]
5. Analysis of Apparent Diffusion Coefficient Value and Dynamic Contrast-Enhanced Magnetic Resonance Imaging Parameters of prostate cancer Patients after Diagnosis and treatment with Magnetic Resonance Imaging.
Gu P
Comput Math Methods Med; 2022; 2022():3111054. PubMed ID: 35785146
[TBL] [Abstract] [Full Text] [Related]
6. Elevated serum CEA is associated with liver metastasis and distinctive circulating tumor DNA alterations in patients with castration-resistant prostate cancer.
Bray AW; Duan R; Malalur P; Drusbosky LM; Gourdin TS; Hill EG; Lilly MB
Prostate; 2022 Sep; 82(13):1264-1272. PubMed ID: 35766303
[TBL] [Abstract] [Full Text] [Related]
7. Safe provision of systemic anti-cancer treatment for urological cancer patients during COVID-19: a tertiary centre experience in the first wave of COVID-19.
So ACP; Karampera C; Khan M; Russell B; Moss C; Monroy-Iglesias MJ; Thillai K; Josephs DH; Pintus E; Rudman S; Van Hemelrijck M; Dolly S; Enting D
BMC Urol; 2022 Apr; 22(1):71. PubMed ID: 35488333
[TBL] [Abstract] [Full Text] [Related]
8. Somatic Features of Response and Relapse in Non-muscle-invasive Bladder cancer Treated with Bacillus Calmette-Guérin Immunotherapy.
Bacon JVW; Müller DC; Ritch E; Annala M; Dugas SG; Herberts C; Vandekerkhove G; Seifert H; Zellweger T; Black PC; Bubendorf L; Wyatt AW; Rentsch CA
Eur Urol Oncol; 2022 Dec; 5(6):677-686. PubMed ID: 34895867
[TBL] [Abstract] [Full Text] [Related]
9. Quantitative prostate MRI Analysis Following Fluvastatin Therapy for Localized prostate cancer - A Pilot Study.
Avery A; Sussman M; Longo J; Menezes RJ; Hamilton RJ; der Kwast THV; Fleshner NE; Penn LZ; Ghai S
Can Assoc Radiol J; 2021 Nov; 72(4):750-758. PubMed ID: 33563030
[TBL] [Abstract] [Full Text] [Related]
10. cancer Statistics, 2021.
Siegel RL; Miller KD; Fuchs HE; Jemal A
CA Cancer J Clin; 2021 Jan; 71(1):7-33. PubMed ID: 33433946
[TBL] [Abstract] [Full Text] [Related]
11. Health expenditures and financial burden among patients with major gastrointestinal cancers relative to other common cancers in the United States.
Rice DR; Farooq A; Hyer JM; Paredes AZ; Bae J; Tsilimigras DI; Pawlik TM
Surgery; 2020 Jun; 167(6):985-990. PubMed ID: 32305231
[TBL] [Abstract] [Full Text] [Related]
12. Linac-based stereotactic body radiation therapy for low and intermediate-risk prostate cancer : Long-term results and factors predictive for outcome and toxicity.
Franzese C; Badalamenti M; Di Brina L; D'Agostino G; Franceschini D; Comito T; Clerici E; Navarria P; Reggiori G; Mancosu P; Tomatis S; Scorsetti M
Strahlenther Onkol; 2020 Jul; 196(7):608-616. PubMed ID: 32303782
[TBL] [Abstract] [Full Text] [Related]
13. MRI-based texture analysis of the primary tumor for pre-treatment prediction of bone metastases in prostate cancer.
Wang Y; Yu B; Zhong F; Guo Q; Li K; Hou Y; Lin N
Magn Reson Imaging; 2019 Jul; 60():76-84. PubMed ID: 30917943
[TBL] [Abstract] [Full Text] [Related]
14. Comparison of
Walacides D; Meier A; Knöchelmann AC; Meinecke D; Derlin T; Bengel FM; Ross TL; Wester HJ; Derlin K; Kuczyk MA; von Klot CAJ; Christiansen H; Henkenberens C
Strahlenther Onkol; 2019 May; 195(5):420-429. PubMed ID: 30610354
[TBL] [Abstract] [Full Text] [Related]
15. Serum Neuroendocrine Markers Predict Therapy Outcome of Patients with Metastatic Castration-Resistant prostate cancer: A Meta-Analysis.
Liu Y; Zhao S; Wang J; Zhu Z; Luo L; Li E; Tang F; Zhao Z
Urol Int; 2019; 102(4):373-384. PubMed ID: 30517936
[TBL] [Abstract] [Full Text] [Related]
16. Clinical and Genomic Characterization of Low-prostate-specific Antigen, High-grade prostate cancer.
Mahal BA; Yang DD; Wang NQ; Alshalalfa M; Davicioni E; Choeurng V; Schaeffer EM; Ross AE; Spratt DE; Den RB; Martin NE; Mouw KW; Orio PF; Choueiri TK; Taplin ME; Trinh QD; Feng FY; Nguyen PL
Eur Urol; 2018 Aug; 74(2):146-154. PubMed ID: 29478736
[TBL] [Abstract] [Full Text] [Related]
17. Intended Versus Inferred treatment After
Hillner BE; Hanna L; Makineni R; Duan F; Shields AF; Subramaniam RM; Gareen I; Siegel BA
J Nucl Med; 2018 Mar; 59(3):421-426. PubMed ID: 29191854
[TBL] [Abstract] [Full Text] [Related]
18. Multiparametric Magnetic Resonance Imaging of prostate cancer Bone Disease: Correlation With Bone Biopsy Histological and Molecular Features.
Perez-Lopez R; Nava Rodrigues D; Figueiredo I; Mateo J; Collins DJ; Koh DM; de Bono JS; Tunariu N
Invest Radiol; 2018 Feb; 53(2):96-102. PubMed ID: 28906339
[TBL] [Abstract] [Full Text] [Related]
19. Avoidance of androgen deprivation therapy in radiorecurrent prostate cancer as a clinically meaningful endpoint for salvage cryoablation.
Ginsburg KB; Elshafei A; Yu C; Jones JS; Cher ML
Prostate; 2017 Oct; 77(14):1446-1450. PubMed ID: 28856702
[TBL] [Abstract] [Full Text] [Related]
20. MiR-26a and miR-138 block the G1/S transition by targeting the cell cycle regulating network in prostate cancer cells.
Erdmann K; Kaulke K; Rieger C; Salomo K; Wirth MP; Fuessel S
J Cancer Res Clin Oncol; 2016 Nov; 142(11):2249-61. PubMed ID: 27562865
[TBL] [Abstract] [Full Text] [Related]
[Next]
